Literature DB >> 21989283

Therapy: Off-label biologics use and infection risk-the great unknown.

Kevin L Winthrop, Josef S Smolen.   

Abstract

Mesh：

Substances：

Year:  2011        PMID： 21989283     DOI： 10.1038/nrrheum.2011.154

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  10 in total

1.  Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry.

Authors:  Benjamin Terrier; Zahir Amoura; Philippe Ravaud; Eric Hachulla; Romain Jouenne; Bernard Combe; Christine Bonnet; Patrice Cacoub; Alain Cantagrel; Michel de Bandt; Olivier Fain; Bruno Fautrel; Philippe Gaudin; Bertrand Godeau; Jean-Robert Harlé; Arnaud Hot; Jean-Emmanuel Kahn; Olivier Lambotte; Claire Larroche; Jean Léone; Olivier Meyer; Béatrice Pallot-Prades; Edouard Pertuiset; Pierre Quartier; Thierry Schaerverbeke; Jean Sibilia; Alexandre Somogyi; Martin Soubrier; Eric Vignon; Brigitte Bader-Meunier; Xavier Mariette; Jacques-Eric Gottenberg
Journal:  Arthritis Rheum       Date:  2010-08

2.  Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial.

Authors:  John H Stone; Janet T Holbrook; Matthew A Marriott; Andrea K Tibbs; Lourdes P Sejismundo; Y-I Min; Ulrich Specks; Peter A Merkel; Robert Spiera; John C Davis; E William St Clair; W Joseph McCune; Steven R Ytterberg; Nancy B Allen; Gary S Hoffman
Journal:  Arthritis Rheum       Date:  2006-05

3.  Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label.

Authors:  Cándido Díaz-Lagares; Roberto Pérez-Alvarez; Francisco J García-Hernández; María M Ayala-Gutiérrez; José Luis Callejas; Agustín Martínez-Berriotxoa; Javier Rascón; Luis Caminal-Montero; Albert Selva-O'Callaghan; Joaquim Oristrell; Carmen Hidalgo; Ricardo Gómez-de-la-Torre; Luis Sáez; Jesús Canora-Lebrato; María-Teresa Camps; Norberto Ortego-Centeno; María-Jesús Castillo-Palma; Manuel Ramos-Casals
Journal:  Arthritis Res Ther       Date:  2011-07-11       Impact factor: 5.156

4.  The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents.

Authors:  Jeffrey R Curtis; Fenglong Xie; Lang Chen; John W Baddley; Timothy Beukelman; Kenneth G Saag; Claire Spettell; Raechele M McMahan; Joaquim Fernandes; Kevin Winthrop; Elizabeth Delzell
Journal:  Ann Rheum Dis       Date:  2011-05-17       Impact factor: 19.103

Review 5.  Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.

Authors:  Tim Bongartz; Alex J Sutton; Michael J Sweeting; Iain Buchan; Eric L Matteson; Victor Montori
Journal:  JAMA       Date:  2006-05-17       Impact factor: 56.272

6.  Safety and retention rate of off-label uses of TNF antagonists in rheumatic conditions: data from the Spanish registry BIOBADASER 2.0.

Authors:  Loreto Carmona; Miguel A Descalzo; Dolores Ruiz-Montesinos; Francisco J Manero-Ruiz; Eva Perez-Pampin; Juan J Gomez-Reino
Journal:  Rheumatology (Oxford)       Date:  2010-07-03       Impact factor: 7.580

7.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010.

Authors:  D E Furst; E C Keystone; J Braun; F C Breedveld; G R Burmester; F De Benedetti; T Dörner; P Emery; R Fleischmann; A Gibofsky; J R Kalden; A Kavanaugh; B Kirkham; P Mease; J Sieper; N G Singer; J S Smolen; P L C M Van Riel; M H Weisman; K Winthrop
Journal:  Ann Rheum Dis       Date:  2011-03       Impact factor: 19.103

8.  Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: data from the French Autoimmunity and Rituximab registry.

Authors:  B Terrier; D Launay; G Kaplanski; A Hot; C Larroche; P Cathébras; B Combe; J P de Jaureguiberry; O Meyer; T Schaeverbeke; A Somogyi; L Tricot; T Zénone; P Ravaud; J E Gottenberg; X Mariette; P Cacoub
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-12       Impact factor: 4.794

Review 9.  An update on mortality in systemic lupus erythematosus.

Authors:  A Ippolito; M Petri
Journal:  Clin Exp Rheumatol       Date:  2008 Sep-Oct       Impact factor: 4.473

10.  Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies.

Authors:  W G Dixon; D P M Symmons; M Lunt; K D Watson; K L Hyrich; A J Silman
Journal:  Arthritis Rheum       Date:  2007-09
  10 in total
  1 in total

1.  Off-label use of the expensive orphan drug eculizumab in France 2009-2013 and the impact of literature: focus on the transplantation field.

Authors:  Johann Castañeda-Sanabria; David Hajage; Melisande Le Jouan; Anne Perozziello; Florence Tubach
Journal:  Eur J Clin Pharmacol       Date:  2016-02-26       Impact factor: 2.953
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.